Get started
MAXCYTE INC COM STK USD0.01 (DI)MAXCYTE INC COM STK USD0.01 (DI)MAXCYTE INC COM STK USD0.01 (DI)

MAXCYTE INC COM STK USD0.01 (DI)

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

MXCT chart


Full chart

MXCT upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪290.99 M‬ GBP
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0 GBP
Net income (FY)
‪−29.79 M‬ GBP
Revenue (FY)
‪32.43 M‬ GBP
Shares float
‪97.34 M‬
Beta (1Y)
0.93

Employees


Employees (FY)
143
Change (1Y)
+18 +14.40%
Revenue / Employee (1Y)
‪288.73 K‬ GBP
Net income / Employee (1Y)
‪−265.20 K‬ GBP

About MaxCyte, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Maher Masoud
Website
maxcyte.com
Headquarters
Rockville
Founded
1998
FIGI
BBG00CFTQNB2
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

MXCT news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of MXCT is 270 GBX — it has increased by 0.10% in the past 24 hours. Watch MAXCYTE INC COM STK USD0.01 (DI) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange MAXCYTE INC COM STK USD0.01 (DI) stocks are traded under the ticker MXCT.
MXCT stock has fallen by −5.50% compared to the previous week, the month change is a −7.53% fall, over the last year MAXCYTE INC COM STK USD0.01 (DI) has showed a −18.92% decrease.
We've gathered analysts' opinions on MAXCYTE INC COM STK USD0.01 (DI) future price: according to them, MXCT price has a max estimate of 847.07 GBX and a min estimate of 500.48 GBX. Watch MXCT chart and read a more detailed MAXCYTE INC COM STK USD0.01 (DI) stock forecast: see what analysts think of MAXCYTE INC COM STK USD0.01 (DI) and suggest that you do with its stocks.
MXCT reached its all-time high on Sep 10, 2021 with the price of 1,236 GBX, and its all-time low was 72 GBX and was reached on Mar 29, 2016. View more price dynamics on MXCT chart.
See other stocks reaching their highest and lowest prices.
MXCT stock is 2.75% volatile and has beta coefficient of 0.93. Track MAXCYTE INC COM STK USD0.01 (DI) stock price on the chart and check out the list of the most volatile stocks — is MAXCYTE INC COM STK USD0.01 (DI) there?
Today MAXCYTE INC COM STK USD0.01 (DI) has the market capitalization of ‪290.99 M‬, it has increased by 1.57% over the last week.
Yes, you can track MAXCYTE INC COM STK USD0.01 (DI) financials in yearly and quarterly reports right on TradingView.
MAXCYTE INC COM STK USD0.01 (DI) is going to release the next earnings report on Apr 23, 2025. Keep track of upcoming events with our Earnings Calendar.
MXCT earnings for the last quarter are −0.08 GBX per share, whereas the estimation was −0.09 GBX resulting in a 8.33% surprise. The estimated earnings for the next quarter are −0.09 GBX per share. See more details about MAXCYTE INC COM STK USD0.01 (DI) earnings.
MAXCYTE INC COM STK USD0.01 (DI) revenue for the last quarter amounts to ‪6.11 M‬ GBX, despite the estimated figure of ‪5.58 M‬ GBX. In the next quarter, revenue is expected to reach ‪6.14 M‬ GBX.
MXCT net income for the last quarter is ‪−8.64 M‬ GBP, while the quarter before that showed ‪−7.42 M‬ GBP of net income which accounts for −16.55% change. Track more MAXCYTE INC COM STK USD0.01 (DI) financial stats to get the full picture.
No, MXCT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 143.00 employees. See our rating of the largest employees — is MAXCYTE INC COM STK USD0.01 (DI) on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MAXCYTE INC COM STK USD0.01 (DI) EBITDA is ‪−31.37 M‬ GBP, and current EBITDA margin is −106.68%. See more stats in MAXCYTE INC COM STK USD0.01 (DI) financial statements.
Like other stocks, MXCT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MAXCYTE INC COM STK USD0.01 (DI) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MAXCYTE INC COM STK USD0.01 (DI) technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MAXCYTE INC COM STK USD0.01 (DI) stock shows the strong sell signal. See more of MAXCYTE INC COM STK USD0.01 (DI) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.